Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, phase I trial, up to 15 participants with resectable PDA. The
study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with
standard-of-care mFOLFIRINOX in the neoadjuvant setting.